RxDoctor Payments Data

Craig Bogdanski, DO

Internal Medicine · Southington, CTNPI 1710986906

Payments from drug & device makers

$701in general payments, 2019–2025

Across 28 payments — averaging $25.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$215
  • Amgen$99
  • Pfizer$82
  • Lilly USA, LLC$71
  • GSK$68
  • Novartis$62
  • plus $104 from 4 others

What the payments were for

  • Food & beverage$54978%
  • Education$15222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$701 in reported general payments places this provider in the 70th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$107,520
Medicare patients
266
Services billed
995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban419$157,293
JardianceEmpagliflozin166$144,793
JanuviaSitagliptin Phosphate93$75,727
XareltoRivaroxaban77$57,505
OzempicSemaglutide55$50,596
TrulicityDulaglutide15$16,566
FarxigaDapagliflozin Propanediol30$15,525
Breo ElliptaFluticasone/Vilanterol29$13,227
GemtesaVibegron50$13,024
Atorvastatin Calcium1,045$12,319
MyrbetriqMirabegron41$12,135
EntrestoSacubitril/Valsartan26$9,793
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$7,368
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,061
Gvoke Hypopen 1-PackGlucagon19$6,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$157,293419 claims
AstraZenecaFarxiga, Symbicort$215$21,07349 claims
GSKBreo Ellipta, Trelegy Ellipta$68$20,28940 claims
Lilly USA, LLCTrulicity$71$16,56615 claims
Astellas Pharma US IncMyrbetriq$34$12,13541 claims
NovartisEntresto$62$9,79326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Southington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →